Breadcrumb Home Departments Urology Institute for Urologic Oncology Research Faculty Labs Dr. Jeremie Calais Lab Videos Institute for Urologic Oncology Videos Sub-navigation Sub-navigation Dr. Jeremie Calais Lab Meet Our Team Publications Research Areas Videos Selected Videos: SNMMIChannel – Best Article of the Month (Feb. 2018)PSMA PET/CT Visualizes Prostate Cancer Recurrence Early, Impacts Radiation Therapy SNMMIChannel – Best Clinical Investigation of the Month (Nov. 2018)Prostate Cancer Radiotherapy More Precisely Targeted with Nuclear Medicine Imaging Urotoday - PCF Carlsbad 2018Effectiveness and Resistance to PSMA Targeted RadioLigand Therapy using 177 Lu-PSMA-617 VJOncology – ASCO GU San Francisco 2019Gallium-labelled PSMA-11 PET/CT and it’s benefitsFluorine-18 FACBC vs. Gallium-labelled PSMA-11 PET/CT for prostate cancer screeningProstate cancer radiotherapy planning with Gallium-labelled PSMA-11 PET/CT imaging Targeted Oncology – AUA Chicago 2019Analyzing Responses to 177LuPSMA-617 in Patients With Metastatic CRPC VJOncology – ASCO Chicago 2019PSMA vs AXUMIN PET/CT in prostate cancerMolecular imaging for prostate cancer salvage radiotherapy planningChallenges with novel molecular imaging techniques for prostate cancer SAR - Prostate Disease Focused Panel Podcast Hot of the Press: PSMA vs Fluciclovine PET/CT for Detection of Prostate Cancer Recurrence SNMMIChannel – Best Clinical Investigation of the Month (Sep. 2019)PET Offers More Precise Screening Method to Select Candidates for Neuroendocrine Tumor Therapy VJOncology – ASCO GU San Francisco 2020The significant impact of PSMA-PET on prostate cancer staging and management eCancer – ASCO GU San Francisco 2020Prostate-specific membrane antigen PET: Who should undergo advanced imaging? Urotoday – ASCO GU San Francisco 2020PSMA PET Diagnostic Imaging in the Current Era VuMedi – ASCO 20202020 ASCO Update on mCRPC: What Is the OS After 177Lu-PSMA-617 Molecular Radiotherapy? VuMedi – UCLA HealthProstate Cancer PET Imaging Biological Target: FACBC vs PSMA PET/CT - Which Option Should Be the Imaging Modality of Choice in Patients With post-RP early BCR? What Is the Best PET Target for Early Biochemical Recurrence of Prostate Cancer? VuMedi – UCLA Health PSMA PET/CT Imaging in Prostate Cancer: GALLIUM-68 vs FLUOR-18 PSMA-PET - Which Option Matters for Detection/Localization of Disease? What Is the Impact on Drug Indication? VuMedi – UCLA Health PSMA PET Imaging for Primary Staging: Efficacy Analysis of Methods for Ruling-out N1 and M1b Disease?
